Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

Exclusion Criteria

• •History of heart attack or cardiovascular disease
• •Known history of arterial or venous thrombosis
• •More than 3 risk factors for thromboembolic events (diabetes, smoker, using oral contraception, using estrogen therapy, hypertriglyceridemia, average cholesterol \> 240 mg/dL, treatment for hypertension)
• •Active cancer or a history of bone marrow disorders
• •Women who are pregnant or nursing
• •History of alcohol/drug abuse or dependence within one year
• •Listed medications dosed within:
• •* 4 weeks of the first dose of the study treatment:
• •* Use of Rituximab
• •* Use of cytotoxic agents
• •* Use of Cyclosporine and other immunomodulators
• •* Use of an investigational drug
• •* 2 weeks of the first dose of the study treatment:
• •* Use of Danazol
• •* Use of Azathioprine
• •* Use of Mycophenolate mofetil and pulsed-dose steroids
• •* 1 week of the first dose of the study treatment:
• •* Use of Anti-D (WinRho®)
• •* Use of IVIG
• •* Had a platelet transfusion
• •* Use of herbal/dietary supplements (excluding vitamins and mineral supplements)
• •* 3 days of the first dose of the study treatment
• •* Use of aspirin, aspirin containing compounds
• •* salicylates
• •* milk of magnesia
• •* non-steroidal anti-inflammatory drugs (unless prescribed for heart disease)
• •History of platelet aggregation that would prevent measurement of platelet counts
• •Known active infection with HIV, hepatitis B, or hepatitis C
• •In the Investigator's opinion, the patient is not able to comply with requirements of the study